EastPharma Ltd was established in 2006 with the aim of becoming a major player in the fast growing emerging markets pharmaceutical industry by means of organic growth, acquisitions and consolidation in fragmented markets.
Since EastPharma Ltd through EastPharma Sarl acquired control of the Turkish generic pharmaceutical company DEVA in 2006, and Saba in 2007. it has applied experienced management expertise to ensure these subsidiaries are in a strong position to increase their market share and profitability.
EastPharma Ltd had been a listed company in London Stock Exchange (LSE) since 2008 until it was delisted on 1st of August 2019 as per local legal requirements.
The first major undertaking of EastPharma Ltd was to facilitate the implementation of DEVA’s new growth strategy, a leading Turkish generic pharmaceuticals company. In 2006, EastPharma became DEVA’s majority shareholder and installed a new management team. The company is headquartered in Istanbul, Turkey, manufactures and sells pharmaceutical generics, formulations and active pharmaceutical ingredients (APIs), and it is one of the leading pharmaceutical companies in Turkey.
EastPharma currently iholds 82,21% of DEVA shares.